Pluri Inc.

NASDAQ PLUR
$5.02 0.17 3.51%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 17.5 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
282.23M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
299.28M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
65.64M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
17.43 %

Upcoming events Pluri Inc.

All events
No upcoming events scheduled

Stock chart Pluri Inc.

Stock analysis Pluri Inc.

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-13.50 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
233.34 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-15.44 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
-0.88 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
467.19 -50.00

Price change Pluri Inc. per year

3.62$ 6.75$
Min Max

Summary analysis Pluri Inc.

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Pluri Inc.

Revenue and net income Pluri Inc.

All parameters

About company Pluri Inc.

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services; cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food-tech, CDMO, and agtech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Address:
Building No. 5, Haifa, Israel, 3508409
Company name: Pluri Inc.
Issuer ticker: PLUR
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2003-06-30
Sector: Healthcare
Industry: Biotechnology
Site: https://www.pluri-biotech.com